Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; David L DeMets; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; John J V McMurray; DAPA-HF Investigators and Committees; Gunnar Hilmar Gislason; Morten Schou

doi:10.2337/dc20-1402

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

Kieran F Docherty, Pardeep S Jhund, Olof Bengtsson, David L DeMets, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, John J V McMurray, DAPA-HF Investigators and Committees, Gunnar Hilmar Gislason (Member of author group), Morten Schou (Member of author group)

26 Citations (Scopus)

Abstract

OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).

RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.

RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.

CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.

Original language	English
Journal	Diabetes Care
Volume	43
Issue number	11
Pages (from-to)	2878-2881
Number of pages	4
ISSN	1935-5548
DOIs	https://doi.org/10.2337/dc20-1402
Publication status	Published - Nov 2020

Access to Document

10.2337/dc20-1402

Cite this

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., McMurray, J. J. V., DAPA-HF Investigators and Committees, Gislason, G. H., & Schou, M. (2020). Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care, 43(11), 2878-2881. https://doi.org/10.2337/dc20-1402

Docherty, KF, Jhund, PS, Bengtsson, O, DeMets, DL, Inzucchi, SE, Køber, L, Kosiborod, MN, Langkilde, AM, Martinez, FA, Sabatine, MS, Sjöstrand, M, Solomon, SD, McMurray, JJV, DAPA-HF Investigators and Committees, Gislason, GH & Schou, M 2020, 'Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy', Diabetes Care, vol. 43, no. 11, pp. 2878-2881. https://doi.org/10.2337/dc20-1402

@article{b990c6fca0bd43c6b6757716f675ccdd,

title = "Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy",

abstract = "OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95\% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.",

author = "Docherty, \{Kieran F\} and Jhund, \{Pardeep S\} and Olof Bengtsson and DeMets, \{David L\} and Inzucchi, \{Silvio E\} and Lars K{\o}ber and Kosiborod, \{Mikhail N\} and Langkilde, \{Anna Maria\} and Martinez, \{Felipe A\} and Sabatine, \{Marc S\} and Mikaela Sj{\"o}strand and Solomon, \{Scott D\} and McMurray, \{John J V\} and \{DAPA-HF Investigators and Committees\} and Gislason, \{Gunnar Hilmar\} and Morten Schou",

note = "{\textcopyright} 2020 by the American Diabetes Association.",

year = "2020",

month = nov,

doi = "10.2337/dc20-1402",

language = "English",

volume = "43",

pages = "2878--2881",

journal = "Diabetes Care",

issn = "1935-5548",

publisher = "American Diabetes Association",

number = "11",

}

TY - JOUR

T1 - Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

AU - Docherty, Kieran F

AU - Jhund, Pardeep S

AU - Bengtsson, Olof

AU - DeMets, David L

AU - Inzucchi, Silvio E

AU - Køber, Lars

AU - Kosiborod, Mikhail N

AU - Langkilde, Anna Maria

AU - Martinez, Felipe A

AU - Sabatine, Marc S

AU - Sjöstrand, Mikaela

AU - Solomon, Scott D

AU - McMurray, John J V

AU - DAPA-HF Investigators and Committees

A2 - Gislason, Gunnar Hilmar

A2 - Schou, Morten

PY - 2020/11

Y1 - 2020/11

N2 - OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.

AB - OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).RESEARCH DESIGN AND METHODS: We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.RESULTS: In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.CONCLUSIONS: In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.

UR - https://www.scopus.com/pages/publications/85093854371

U2 - 10.2337/dc20-1402

DO - 10.2337/dc20-1402

M3 - Journal article

C2 - 33082245

SN - 1935-5548

VL - 43

SP - 2878

EP - 2881

JO - Diabetes Care

JF - Diabetes Care

IS - 11

ER -

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this